Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Kurzrock R, et al. Among authors: brenner a. Mol Cancer Ther. 2012 Feb;11(2):308-16. doi: 10.1158/1535-7163.MCT-11-0566. Epub 2011 Dec 27. Mol Cancer Ther. 2012. PMID: 22203732 Clinical Trial.
RANK ligand: effects of inhibition.
George S, Brenner A, Sarantopoulos J, Bukowski RM. George S, et al. Among authors: brenner a. Curr Oncol Rep. 2010 Mar;12(2):80-6. doi: 10.1007/s11912-010-0088-1. Curr Oncol Rep. 2010. PMID: 20425591 Review.
Phase I study of GRN1005 in recurrent malignant glioma.
Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Drappatz J, et al. Among authors: brenner a. Clin Cancer Res. 2013 Mar 15;19(6):1567-76. doi: 10.1158/1078-0432.CCR-12-2481. Epub 2013 Jan 24. Clin Cancer Res. 2013. PMID: 23349317 Clinical Trial.
Predicting success in regulatory approval from Phase I results.
Malik L, Mejia A, Parsons H, Ehler B, Mahalingam D, Brenner A, Sarantopoulos J, Weitman S. Malik L, et al. Among authors: brenner a. Cancer Chemother Pharmacol. 2014 Nov;74(5):1099-103. doi: 10.1007/s00280-014-2596-4. Epub 2014 Sep 23. Cancer Chemother Pharmacol. 2014. PMID: 25245822 Free PMC article.
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS. Hong DS, et al. Br J Cancer. 2020 May;122(11):1630-1637. doi: 10.1038/s41416-020-0802-1. Epub 2020 Apr 2. Br J Cancer. 2020. PMID: 32238921 Free PMC article. Clinical Trial.
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
Sampson JH, Singh Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Mardor Y, Merchant F, Merchant N, Randazzo D, Vogelbaum M, Vrionis F, Wembacher-Schroeder E, Zabek M, Butowski N. Sampson JH, et al. Among authors: brenner a. Neuro Oncol. 2023 Jun 2;25(6):1085-1097. doi: 10.1093/neuonc/noac285. Neuro Oncol. 2023. PMID: 36640127 Free PMC article.
783 results